The latest price target for PainReform (NASDAQ:PRFX) was reported by Maxim Group on June 26, 2024. The analyst firm set a price target for $2.00 expecting PRFX to rise to within 12 months (a possible 257.14% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for PainReform (NASDAQ:PRFX) was provided by Maxim Group, and PainReform reiterated their buy rating.

There is no last upgrade for PainReform

There is no last downgrade for PainReform.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PainReform, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PainReform was filed on June 26, 2024 so you should expect the next rating to be made available sometime around June 26, 2025.

While ratings are subjective and will change, the latest PainReform (PRFX) rating was a reiterated with a price target of $2.00 to $2.00. The current price PainReform (PRFX) is trading at is $0.56, which is out of the analyst’s predicted range.